ADOCIA SAS (ADOC.PA)
FR0011184241 - Common Stock
Overall ADOC gets a fundamental rating of 2 out of 10. We evaluated ADOC against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of ADOC have multiple concerns. ADOC has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ADOC had negative earnings in the past year.
In the past year ADOC has reported a negative cash flow from operations.
In the past 5 years ADOC always reported negative net income.
ADOC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -84.80%, ADOC is not doing good in the industry: 77.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.8% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.02%
ROA(5y)-52.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 64.42%, ADOC is doing good in the industry, outperforming 70.59% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ADOC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADOC has been increased compared to 1 year ago.
Compared to 5 years ago, ADOC has more shares outstanding
Compared to 1 year ago, ADOC has an improved debt to assets ratio.
2.2 Solvency
ADOC has an Altman-Z score of -1.69. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
ADOC's Altman-Z score of -1.69 is on the low side compared to the rest of the industry. ADOC is outperformed by 60.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.69 |
ROIC/WACCN/A
WACC8.14%
2.3 Liquidity
ADOC has a Current Ratio of 1.02. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC has a Current ratio of 1.02. This is in the lower half of the industry: ADOC underperforms 79.41% of its industry peers.
A Quick Ratio of 1.01 indicates that ADOC should not have too much problems paying its short term obligations.
The Quick ratio of ADOC (1.01) is worse than 72.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
The earnings per share for ADOC have decreased strongly by -148.31% in the last year.
ADOC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -81.22%.
The Revenue for ADOC have been decreasing by -46.13% on average. This is quite bad
EPS 1Y (TTM)-148.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.04%
Revenue 1Y (TTM)-81.22%
Revenue growth 3Y36.74%
Revenue growth 5Y-46.13%
Sales Q2Q%-87.24%
3.2 Future
Based on estimates for the next years, ADOC will show a small growth in Earnings Per Share. The EPS will grow by 0.53% on average per year.
ADOC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.43% yearly.
EPS Next Y47.15%
EPS Next 2Y15.82%
EPS Next 3Y0%
EPS Next 5Y0.53%
Revenue Next Year68.06%
Revenue Next 2Y35.4%
Revenue Next 3Y31.04%
Revenue Next 5Y23.43%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ADOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 1.52, the valuation of ADOC can be described as very cheap.
95.59% of the companies in the same industry are more expensive than ADOC, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of ADOC to the average of the S&P500 Index (21.99), we can say ADOC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.52 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ADOC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.82%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ADOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADOCIA SAS
EPA:ADOC (9/16/2024, 11:49:42 AM)
5.615
+0.04 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap84.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.52 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.8% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-148.31%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y47.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-81.22%
Revenue growth 3Y36.74%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y